A Multicenter Prospective Randomized Study of Fully Covered Metallic Stent versus Tube Stent in Patients with Borderline Resectable Pancreatic Carcinoma

A Multicenter Prospective Randomized Study of Fully Covered Metallic Stent versus Tube Stent in Patients with Borderline Resectable Pancreatic Carcinoma - TOBIP-01/NUPAT-04

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024832

Enrollment

Registered

2017-01-01

Start date

2017-03-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic carcinoma

Interventions

tube stent (more than 8.5 Fr) Fully covered metallic stent (more than 8 mm)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Borderline resectable Pancreatic ductal carcinoma case with bile duct stenosis (image diagnosis) Cases planed NAC(R)T more than 2 month PS(ECOG) 0 or 1 Adequate oral intake Estimated life expectancy more than 3 months Without another malignant disease With informed concent

Exclusion criteria

Exclusion criteria: Severe neurologic impairment or mental disorder With severe other organ disorder Pregnant or lactating women,

Design outcomes

Primary

Measure	Time frame
Rate of cases who do not need stent exchange until surgical operation or diagnosis of inoperation	—

Countries

Japan

Contacts

Public ContactHiroki Kawashima

Nagoya University Graduate School of Medicine Department of Gastroenterology and Hepatology

h-kawa@med.nagoya-u.ac.jp0527442166

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026